Recent

% | $
Quotes you view appear here for quick access.

Eli Lilly and Company Message Board

gringo33339 6 posts  |  Last Activity: May 11, 2015 7:46 AM Member since: Dec 9, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    3 quarters or less left of cash!

    by jay.gittes May 8, 2015 4:40 PM
    gringo33339 gringo33339 May 11, 2015 7:46 AM Flag

    That's why I said "should" and not "will". You can look at the rate of revenue growth and make an educated guess that the lender isn't going to make the terms so restrictive that the company will be unable to access the cash. They are already being compensated for risk via the high rate.

  • Reply to

    3 quarters or less left of cash!

    by jay.gittes May 8, 2015 4:40 PM
    gringo33339 gringo33339 May 9, 2015 8:26 PM Flag

    Minimum revenue milestones. The lender wants to make sure the company will be able to repay, so additional borrowings are subject to conditions. The amount of the thresholds are not public.

  • Reply to

    3 quarters or less left of cash!

    by jay.gittes May 8, 2015 4:40 PM
    gringo33339 gringo33339 May 9, 2015 10:45 AM Flag

    Why gaga, it sounds like you have some bad blood. Perhaps you could stop by the old clinic and we'll try to filter out the badness... Bwahahahaha!

  • Reply to

    3 quarters or less left of cash!

    by jay.gittes May 8, 2015 4:40 PM
    gringo33339 gringo33339 May 8, 2015 9:06 PM Flag

    Those numbers look right but you are missing the $20m in untapped cash from the term loan. That should carry them to positive cash flow.

  • gringo33339 by gringo33339 May 7, 2015 10:48 PM Flag

    Very good CC. Most positive vibe in a year. Look for a nice uptrend to be established.

  • gringo33339 by gringo33339 Mar 13, 2015 7:39 AM Flag

    Given prior suspension of guidance I don't think the miss matters much. The stock will likely move down as a knee jerk reaction to the lower than expected numbers, but don't discount the longer-term impact of the move to stop diluting shareholders. That is very rare in a company at TEAR's stage of development where most fall prey to convertible preferred issuances that result in a death spiral of dilution and manipulation.

    Guidance or no guidance? The CC Q&Q includes a question about guidance. The answer - we don't want to provide guidance but we really think we can beat this year's 35% growth rate **wink wink**

    What's in a name? I'm losing track of the different names these guys are slapping on their sales programs. Its time to execute.

    New device? Expectation of a new device by end of 2015 (for use in studies) is interesting but given the long slog to get approval for the first device, CLIA, acceptance by medical community, sales, .... a road we are still on, I don't think there is really any value being attributed to this yet. Maybe there will be in 18 months.

    GLTA

LLY
74.30+0.03(+0.04%)May 22 4:01 PMEDT